Cadila gets nod for H1N1 vaccine in India

MUMBAI Wed May 12, 2010 12:05pm IST

A man walks past a graffiti about H1N1 influenza on a street side wall in Mumbai September 9, 2009. Cadila Healthcare Ltd said on Wednesday it has received approval from the Drug Controller General of India to market the H1N1 vaccine in the country.  REUTERS/Arko Datta/Files

A man walks past a graffiti about H1N1 influenza on a street side wall in Mumbai September 9, 2009. Cadila Healthcare Ltd said on Wednesday it has received approval from the Drug Controller General of India to market the H1N1 vaccine in the country.

Credit: Reuters/Arko Datta/Files

Related Topics

Priyanka Gandhi Vadra, daughter of Congress party chief Sonia Gandhi, adjusts her flower garlands as she campaigns for her mother during an election meeting at Rae Bareli in Uttar Pradesh April 22, 2014. REUTERS/Pawan Kumar

Election 2014

More than 814 million people — a number larger than the population of Europe — are eligible to vote in the world’s biggest democratic exercise.  Full Coverage 

MUMBAI (Reuters) - Cadila Healthcare Ltd said on Wednesday it has received approval from the Drug Controller General of India (DCGI) to market its H1N1 vaccine in the country.

Used to prevent the infection of swine flu, this egg-based vaccine named 'VaxiFlu-S' will be marketed by Vaxxicare, a division of the company, it said in a statement.

Indian drumakers such as Panacea Biotec and Pune-based unlisted vaccines maker Serum Institute are also close to launch an H1N1 vaccine in the country.

Out of the 139,466 people tested for swine flu symptoms in India since the outbreak of the pandemic in the year 2009, about 23 percent have tested positive for swine flu, Cadila said in a statement.

"The development is positive for the company as India has a huge population of people aged above 60 years and below 15 years," a pharma sector analyst told Reuters over the telephone.

"While Panacea Biotec is looking to sell the vaccine to the government, Cadila has a focus on direct domestic market. This would help company make early in-roads," another analyst said.

The market size for H1N1 vaccine in India in case of high-risk population was about 4-5 million doses, Pankaj Patel, chairman and managing director of Cadila had told Reuters.

Cadila also plans to develop more vaccines against bacterial, viral and protozoal infections at its vaccine technology centre, it said in the statement.

At 11:32 a.m., shares of Cadila Healthcare were trading at 586 rupees, up 1.97 percent in a flat Mumbai market.

(Reporting by Kaustubh Kulkarni, Editing by Ramya Venugopal)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Iran Oil Payment

Iran Oil Payment

India to make May-July oil payments to Iran - sources  Full Article 

Ferry Tragedy

Ferry Tragedy

Children's corpses in Korean ferry reveal desperate attempts to escape.  Full Article 

Ukraine Crisis

Ukraine Crisis

Russia says it will respond if Ukraine interests attacked.  Full Article 

Reassuring Allies

Reassuring Allies

Obama seeks to ease Asian allies' doubts during visit to Japan.  Full Article 

Moyes Speaks

Moyes Speaks

Sacked Moyes thanks Ferguson for Man Utd opportunity.  Full Article 

Mobile Ads

Mobile Ads

Google extends reach into mobile apps with new ad feature.  Full Article 

Allegations Denied

Allegations Denied

Allegations of teen sex abuse by three Hollywood execs denied.  Full Article 

Need for Speed

Need for Speed

United must move fast with vital window looming.  Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage